Bryostatin and Vincristine in B-Cell Malignancies

Inclusion Criteria: Patients with biopsy proven B-cell malignancies [e.g. chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM)]; HIV-associated lymphomas and acute leukemias are not eligible Performance status: ECOG 0, 1, or 2 Life expectancy of at least 12 weeks Patients with aggressive NHL will be enrolled after having failed all possible therapy with curative intent Patients with CLL must have failed an alkylating agent-containing regimen as well as fludarabine chemotherapy Patients with multiple myeloma must have received at least one prior chemotherapy regimen and not be eligible for a dose intensification treatment approach At least 4 weeks must have elapsed since prior large-field radiation therapy Patients must have been off previous anti-cancer therapy for at least 3 weeks (6 weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity Prior vincristine therapy is allowed Sexually active men and women must use an accepted and effective method of contraception In women of child-bearing age, a pregnancy test may be done at the discretion of the investigator Must have given written informed consent Exclusion Criteria: Patients with brain metastasis, leptomeningeal involvement, primary CNS NHL, and acute leukemia are ineligible Patients with HIV infection are ineligible WBC < 3000/ul Granulocytes < 1500/ul Platelets < 50,000/ul Hemoglobin =< 8.5 g/dl Bilirubin > 1.5 mg/dl AST and ALT > 2 times normal Creatinine > 2.0 mg/dl, and/or actual creatinine clearance < 40 ml/min/1.73 m^2; all patients are required to have a 24 hr creatinine clearance Clinical evidence of bleeding diathesis ECOG Performance status 3 or 4 Patients who are pregnant or lactating; vincristine can cause fetal harm Patients with clinically apparent neuropathy are ineligible (>= grade 2 neuropathy)